Prospective Evaluation of Diagnostic Performance of PanTum Detect Test in Adult Patients With Suspected or Confirmed Macroscopic Solid Pre-malignant or Malignant Lesion(s) Referred to Fludeoxyglucose (18F) PET/CT and in Adult Healthy Population

Inclusion Criteria: To be eligible to participate in this trial, an individual must meet all the following criteria: Group A * Age 18-88 years at inclusion (Man, Woman) * Suspected or confirmed macroscopic solid pre-malignant or malignant lesion(s) * Availability of result of FDG PET/CT performed -30 to-15 days or up to +30 days from trial intervention and performed as a standard of care * Willingness to undergo trial intervention * Signed informed consent * Absence of any of exclusion criteria Group B * Age 18-88 years at inclusion (Man, Woman) * Considered as free of pre-malignant or malignant lesion(s) at the time of inclusion * Willingness to undergo trial intervention * Signed informed consent * Absence of any of exclusion criteria Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this trial: For Group A and B 1. Acute Illness, Organ Transplantation, Surgeries, and injuries are an exclusion criteria: e.g. bone fracture, deep cut (deeper 0.5 cm and/or larger than 1 cm), abrasion (greater than 5 cm in diameter), open wound, contusion, torn ligaments, blood in the stool, blood in the urine. After successful recovery the waiting period must be 8 weeks. 2. Medication: Any treatment or activity that could impact the immune system must be considered as an exclusion criteria.These includes. 1. Steroid-, chemo-, radio therapy in last 8 weeks 2. Immunesuppression using following active ingredients; Methotrexate, Cyclosporine, Azathioprine, Tacrolimus, Mycophenolate, Rapamycin, Sirolimus, Mycophenolat-Mofetil in last 8 weeks. 3. Granulocyte-Macrophage Colony-Stimulating Factor (GM-SCF); Molgramostim, Sargramostim in last 8 weeks o Amygdalin (Vitamin B17) in last 4 weeks 4. Immune modulation using Corticosteroids, Glucocorticoids and Colchicine (Cortison/hydrocortisone \>5 mg/day, Budesonid \>5 mg/day) in last 4 weeks 5. Non-Steroidal anti-inflammatory drugs (NSAIDs) \& CGRP including in last 2 weeks. An occasional use of Ibuprofen, Paracetamol and Aspirin is not an exclusion criteria. 6. Antibiotics and Antifungals in last 2 weeks 3. Vaccination: any vaccination in last 4 weeks. 4. Infection: Acute Bacterial, Viral infection and Fungal infection in last 2 weeks. 5. Imaging Investigation using contrast medium in last 2 weeks. 6. Dialysis on the day of blood draw. 7. Genetic disorder such as thrombocytopenia may leads to rejection of test due to reduced amount of Blood Cells. For Group B only: 1\. Previous and Current Cancer: In case of previously diagnosed and successfully treated Tumour \& cancer, the PanTum Detect test should be done 5 years after the successful treatment \& cure. This applies to all kind of Tumour and Cancers. all currently ongoing cancer treatments and newly diagnosed cancer including ongoing diagnostic procedures are an exclusion criterion